The Promise of Home Monitoring in Retinal Disease Management
Overview
Home-based remote patient monitoring (RPM) for retinal diseases, particularly age-related macular degeneration (AMD), shows promise in improving patient outcomes and clinic efficiency. FDA-approved home OCT devices and functional testing have demonstrated better visual acuity at conversion and reduced clinic visit frequency, while addressing practice workflow and reimbursement concerns.
Background
Remote patient monitoring is rapidly expanding in medicine, with Medicare spending increasing significantly from 2019 to 2023. Home monitoring enables disease surveillance aligned with progression rather than fixed clinic visits, reducing patient burden. In ophthalmology, preferential hyperacuity perimetry (PHP) and home OCT devices have been developed to monitor retinal diseases such as AMD. These technologies allow earlier detection of disease progression and timely treatment, potentially improving visual outcomes and clinic workflow.
Data Highlights
| Metric | Value | Source |
|---|---|---|
| Medicare RPM Spending | $6.8 million (2019) to $194.5 million (2023) | Ref 1 |
| Visual Acuity Improvement at Conversion (HOME Study) | 5 letters better with ForeseeHome vs. Amsler grid | Ref 2 |
| Reduction in NVAMD Visit Frequency | Nearly 48% | Ref 6 |
| NVAMD Patient Discontinuation Rate after 2 Years | 38% | Ref 7 |
Key Findings
- Home-based functional testing (ForeseeHome) improves visual acuity at wet AMD conversion by 5 letters compared to standard monitoring.
- FDA-approved home OCT (SCANLY Home OCT) enables quantitative monitoring of retinal fluid, alerting physicians to disease progression remotely.
- Outsourcing patient education, device training, and adherence monitoring to external RPM providers reduces burden on retina clinics and improves patient compliance.
- RPM billing codes allow practices to generate recurring revenue every 30 days for professional data review services, potentially increasing practice productivity.
- Home monitoring may reduce clinic visit frequency by nearly 48% for neovascular AMD patients, helping manage increasing patient volumes and clinic capacity constraints.
- Patient retention is a challenge in AMD care, with 38% discontinuing treatment after 2 years; home monitoring may improve compliance by enabling safer extension of treatment intervals.
Clinical Implications
Incorporating home monitoring into retinal disease management can enhance early detection and timely treatment, improving visual outcomes. Practices can leverage partnerships with RPM service providers to manage workflow and patient adherence efficiently. Additionally, home monitoring offers a new revenue stream through professional billing codes and may alleviate clinic capacity issues by reducing visit frequency.
Conclusion
Home monitoring represents a promising advancement in retinal disease care, offering improved patient outcomes, enhanced clinic efficiency, and sustainable revenue opportunities. Successful integration depends on collaboration with RPM providers and adapting practice workflows to this evolving technology.
References
- Medicare RPM Spending Data 2019-2023
- HOME Study -- ForeseeHome in Intermediate AMD
- Real-World Study Supporting ForeseeHome Effectiveness
- FDA Approval of SCANLY Home OCT
- Home OCT Quantitative Monitoring and Alerts
- Study on Visit Frequency Reduction with Home OCT
- NVAMD Patient Discontinuation Rates
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.